NCT06339788View on ClinicalTrials.gov

Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 10, 2024

Primary Completion Date

June 12, 2024

Study Completion Date

June 12, 2024

Conditions
Healthy Volunteers
Interventions
DRUG

HD-P023

Single dose administration of HD-P023

DRUG

Teneligliptin

Single does administration of Teneligliptin and Empagliflozin High

DRUG

Empagliflozin

Single does administration of Teneligliptin and Empagliflozin High

Trial Locations (1)

Unknown

Central Hospital, Siheung-si

Sponsors

Lead Sponsor

Handok Inc.
All Listed Sponsors
lead

Handok Inc.

INDUSTRY

NCT06339788 - Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers | Biotech Hunter | Biotech Hunter